相似文献
1
Liposomes in diagnosis and treatment of cardiovascular disorders.
Methodist Debakey Cardiovasc J. 2012 Jan;8(1):36-41. doi: 10.14797/mdcj-8-1-36.
2
Liposomes for cardiovascular targeting.
Ther Deliv. 2012 Apr;3(4):501-14. doi: 10.4155/tde.12.18.
3
Liposome technology for cardiovascular disease treatment and diagnosis.
Expert Opin Drug Deliv. 2012 Feb;9(2):249-65. doi: 10.1517/17425247.2012.647908. Epub 2012 Jan 11.
4
Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents.
Immunomethods. 1994 Jun;4(3):244-58. doi: 10.1006/immu.1994.1027.
5
A novel approach for establishing cardiovascular drug efficacy.
Nat Rev Drug Discov. 2014 Dec;13(12):942. doi: 10.1038/nrd4090-c2. Epub 2014 Nov 14.
6
Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress.
Future Cardiol. 2015 May;11(3):281-6. doi: 10.2217/fca.15.20.
7
The Heart's Circadian Rhythms Point to Potential Treatment Strategies.
Circulation. 2016 Dec 6;134(23):1907-1908. doi: 10.1161/CIRCULATIONAHA.116.026039.
8
Ultrasound techniques for drug delivery in cardiovascular medicine.
Curr Drug Discov Technol. 2008 Dec;5(4):328-32. doi: 10.2174/157016308786733573.
9
Future directions of liposome- and immunoliposome-based cancer therapeutics.
Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. doi: 10.1053/j.seminoncol.2004.08.009.
10
[Value of pharmacokinetic studies in cardiology].
Kardiologiia. 1989 May;29(5):5-11.
引用本文的文献
1
Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis.
Polymers (Basel). 2024 May 16;16(10):1421. doi: 10.3390/polym16101421.
2
Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.
Adv Sci (Weinh). 2023 Oct;10(29):e2302918. doi: 10.1002/advs.202302918. Epub 2023 Sep 12.
3
Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation.
Front Drug Deliv. 2022;2. doi: 10.3389/fddev.2022.908709. Epub 2022 Jul 5.
4
Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.
Pharmaceutics. 2022 Mar 26;14(4):711. doi: 10.3390/pharmaceutics14040711.
5
High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer.
Front Bioeng Biotechnol. 2022 Feb 7;9:817768. doi: 10.3389/fbioe.2021.817768. eCollection 2021.
6
A Comprehensive Review on the Applications of Exosomes and Liposomes in Regenerative Medicine and Tissue Engineering.
Polymers (Basel). 2021 Jul 30;13(15):2529. doi: 10.3390/polym13152529.
7
Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction.
Sci Rep. 2020 Oct 6;10(1):16596. doi: 10.1038/s41598-020-73593-0.
8
Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.
Int J Nanomedicine. 2020 May 28;15:3803-3826. doi: 10.2147/IJN.S242516. eCollection 2020.
9
Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.
Nanomedicine. 2017 Nov;13(8):2565-2574. doi: 10.1016/j.nano.2017.07.005. Epub 2017 Jul 25.
10
Tissue plasminogen activator-based clot busting: Controlled delivery approaches.
Glob Cardiol Sci Pract. 2014 Oct 16;2014(3):336-49. doi: 10.5339/gcsp.2014.46. eCollection 2014.
本文引用的文献
1
Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques.
Int J Nanomedicine. 2011;6:1279-90. doi: 10.2147/IJN.S18739. Epub 2011 Jun 21.
2
Development and physico-chemical characterization of a liposomal formulation of istaroxime.
Eur J Pharm Biopharm. 2011 Oct;79(2):285-93. doi: 10.1016/j.ejpb.2011.04.013. Epub 2011 Apr 29.
3
Theranostic nanomedicine.
Acc Chem Res. 2011 Oct 18;44(10):1029-38. doi: 10.1021/ar200019c. Epub 2011 May 5.
4
Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model--brief report.
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1357-9. doi: 10.1161/ATVBAHA.111.225938. Epub 2011 Mar 24.
5
Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication.
ACS Nano. 2010 Dec 28;4(12):7552-8. doi: 10.1021/nn101924a. Epub 2010 Nov 10.
6
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis.
Mol Pharm. 2010 Dec 6;7(6):2020-9. doi: 10.1021/mp100309y. Epub 2010 Nov 8.
7
Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents.
Int J Pharm. 2011 Jan 17;403(1-2):254-61. doi: 10.1016/j.ijpharm.2010.10.028. Epub 2010 Oct 31.
8
An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy.
J Control Release. 2010 Oct 15;147(2):269-77. doi: 10.1016/j.jconrel.2010.07.127. Epub 2010 Aug 6.
9
Ultrasound-enhanced delivery of targeted echogenic liposomes in a novel ex vivo mouse aorta model.
J Control Release. 2010 Jun 15;144(3):288-95. doi: 10.1016/j.jconrel.2010.02.030. Epub 2010 Mar 2.
10
Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research.
J Thromb Thrombolysis. 2010 Jul;30(1):29-35. doi: 10.1007/s11239-010-0450-z.
Zotero 插件